Chandra Bhagat Pharma share price
BSE: 542934Pharmaceuticals & BiotechnologySmall Cap
Chandra Bhagat Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2020
Last close ₹47.18up ₹4.28 (9.98%)
Share price at the BSE close on 28 Oct 2026. Previous close ₹42.90.
28 Oct: open ₹47.19, high ₹47.19, low ₹47.18
52-week range of traded prices to 28 Oct 2026
₹29.70Low, 6 May 2026₹52.99High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹36 Cr3,869th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 12.60
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.50
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 7,000
Results
Standalone; ₹ crore.Chandra Bhagat Pharma half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +34.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +229.5%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹91 Crup 255.15%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹2.60 Crup 1,035.59%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 2.9%
Revenue by half year
Peak revenue ₹119 Cr, half year to Sep 2023; lowest ₹22 Cr, half year to Mar 2025
Net profit by half year, a loss in red
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44 | 75 | 119 | 102 | 65 | 22 | 26 | 91 |
| Net profit | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
| Net margin | 0.8% | 0.7% | 0.5% | 0.9% | 1.1% | 0.8% | 0.9% | 2.9% |
Standalone. The last eight half years. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹116 Crup 34.08%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3.05 Crup 255.12%
- Net margin
- 2.6%
Revenue by year
Peak revenue ₹221 Cr, year to Mar 2024; lowest ₹71 Cr, year to Mar 2021
Net profit by year, a loss in red
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 94 | 71 | 94 | 120 | 221 | 87 | 116 |
| Net profit | 0 | 0 | 1 | 1 | 2 | 1 | 3 |
| Net margin | 0.3% | 0.3% | 0.8% | 0.8% | 0.7% | 1.0% | 2.6% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMA, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −41.7% | +254.4% | −83.6% | 0.0% |
| 3 years | −32.0% | +49.9% | −54.6% | 0.0% |
| 5 years | −5.1% | +74.5% | −45.6% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Chandra Bhagat Pharma insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Directors and key managers1 purchase, 0 sales₹0.25 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.25 Cr
- Promoters and promoter group: no market trade · 7 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Chandra Bhagat Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Chandra Bhagat Pharma in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Kabra DrugsKABRADG | 39 | 5.08 | 1.30 | +1,743.5% | – | 28.0% | 28.4% | 0.00% |
 Bharat Immunologicals & BiologicalsBIBCL | 38 | – | – | – | – | – | – | 0.00% |
 Vista PharmaceuticalsVISTAPH | 38 | – | 1.04 | −60.4% | – | −28.7% | −32.5% | 0.00% |
 Medicamen OrganicsMEDIORG | 38 | – | – | −40.7% | −199.3% | −13.7% | – | 0.00% |
 Sandu PharmaceuticalsSANDUPHQ | 36 | 20.09 | 0.81 | +4.2% | +10.3% | 4.1% | 5.3% | 2.72% |
 Rajnish WellnessRAJNISH | 36 | – | 0.35 | +356.9% | – | – | −8.2% | 0.00% |
 Roopa IndustriesROOPAIND | 34 | 261.57 | 1.90 | +3.7% | −93.7% | 0.7% | 15.4% | 0.00% |
 Jfl Life SciencesJFLLIFE | 33 | 4.87 | 0.72 | – | – | 15.9% | 15.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Chandra Bhagat Pharma announcements
Oct 2026
22 Oct · Announcement under Regulation 30 (LODR)-Allotment
21 Oct · Certificate For Non-Applicability Of Corporate Governance For The Quarter Ended 30Th September, 2026.
Chandra Bhagat Pharma share price by year
Each calendar year to 2025.Chandra Bhagat Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 41.25 | −37.2% | 70.99 | 35.00 |
| 2024 | 65.67 | −43.9% | 147.50 | 63.10 |
| 2023 | 117.05 | +3.6% | 154.35 | 90.25 |
| 2022 | 113.00 | +25.6% | 138.00 | 77.25 |
| 2021 | 90.00 | +100.0% | 147.50 | 38.25 |
| 2020 | 45.00 | – | 53.05 | 31.15 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 14 Feb 2020.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 42.90 | 42.90 | 42.90 | 42.90 | 42.90 | 2,000 |
| 26 Oct 2026 | 42.90 | 42.90 | 42.90 | 42.90 | 42.90 | 1,000 |
| 23 Oct 2026 | 39.00 | 39.00 | 39.00 | 39.00 | 39.00 | 2,000 |
| 19 Oct 2026 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 2,000 |
| 16 Oct 2026 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 2,000 |
| 13 Oct 2026 | 35.02 | 41.80 | 35.02 | 41.80 | 37.28 | 3,000 |
| 8 Oct 2026 | 42.00 | 42.00 | 38.14 | 38.20 | 41.65 | 66,000 |
| 7 Oct 2026 | 42.37 | 42.37 | 42.37 | 42.37 | 42.37 | 8,000 |
| 6 Oct 2026 | 44.59 | 44.59 | 44.59 | 44.59 | 44.59 | 4,000 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 542934
- ISIN
- INE07QQ01016
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.cbcpharma.com
- CIN
- L24230MH2003PLC139534
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2003
- Registered office
- 323-F, Bhagat Bhuvan, Dr Ambedkar Road, Matunga (East), Mumbai 400019, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments